First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) Stock Short Interest Drops 50.2%

Posted by George Bondi on Oct 14th, 2026

First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH – Get Free Report) was the recipient of a large decrease in short interest in September. As of September 30th, there was short interest totaling 9,470 shares, a decrease of 50.2% from the September 15th total of 19,031 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 468,724 shares, the short-interest ratio is presently 0.0 days.

First Trust Nasdaq Pharmaceuticals ETF Stock Performance

Shares of FTXH stock traded up $0.86 during trading hours on Wednesday, hitting $41.29. 32,672 shares of the company were exchanged, compared to its average volume of 233,511. The company has a 50 day simple moving average of $41.07 and a two-hundred day simple moving average of $37.70. The firm has a market cap of $1.07 billion, a P/E ratio of 14.51 and a beta of 0.45. First Trust Nasdaq Pharmaceuticals ETF has a fifty-two week low of $28.85 and a fifty-two week high of $43.52.

First Trust Nasdaq Pharmaceuticals ETF Cuts Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 30th. Investors of record on Thursday, September 24th were paid a dividend of $0.0113 per share. This is a drop from First Trust Nasdaq Pharmaceuticals ETF’s previous quarterly dividend of $0.0920. This represents a $0.05 annualized dividend and a yield of 0.1%. The ex-dividend date of this dividend was Thursday, September 24th.

Institutional Investors Weigh In On First Trust Nasdaq Pharmaceuticals ETF

A number of large investors have recently bought and sold shares of FTXH. MinichMacGregor Wealth Management LLC acquired a new position in shares of First Trust Nasdaq Pharmaceuticals ETF during the third quarter valued at about $968,000. Compass Financial Management LLC acquired a new stake in shares of First Trust Nasdaq Pharmaceuticals ETF in the 2nd quarter valued at about $29,000. Nilsine Partners LLC raised its stake in First Trust Nasdaq Pharmaceuticals ETF by 3.5% during the 2nd quarter. Nilsine Partners LLC now owns 28,057 shares of the company’s stock worth $1,071,000 after buying an additional 937 shares during the period. Finally, Vivaldi Capital Management LP boosted its holdings in First Trust Nasdaq Pharmaceuticals ETF by 16.0% in the first quarter. Vivaldi Capital Management LP now owns 12,590 shares of the company’s stock worth $433,000 after acquiring an additional 1,741 shares in the last quarter.

About First Trust Nasdaq Pharmaceuticals ETF

(Get Free Report)

The First Trust Nasdaq Pharmaceuticals ETF (FTXH) is an exchange-traded fund that is based on the Nasdaq US Smart Pharmaceuticals index. The fund tracks the 30 most liquid US pharmaceutical companies, weighted according to factors related to value, volatility, and growth. FTXH was launched on Sep 20, 2016 and is managed by First Trust.